Printer Friendly

Antithrombotic/Anticoagulant Drugs: World Market 2012-2022.

NEW YORK, May 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0325493/Antithrombotic/Anticoagulant-Drugs-World-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Where are antithrombotic and anticoagulant treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.

This study assesses drugs to treat abnormal blood clotting in human beings. Discover sales predictions at world market, therapeutic class, product and national levels to 2022.

How will products - Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra, Aspirin Cardio, Effient, Pradaxa, Brilinta and others - perform? Our report gives you business research and analysis with many sales predictions. See the future of the industry and market.

Also, receive forecasting of submarkets, finding potential sales trends from 2012:

-- Platelet aggregation inhibitors

-- Heparins

-- Fibrinolytics

-- Vitamin K antagonists

-- Direct thrombin inhibitors

-- Direct factor Xa inhibitors.

Our report discusses activities of Eli Lilly, Boehringer Ingelheim, AstraZeneca, J&J, Bayer, Sanofi, Merck, Eisai, Daiichi Sankyo and other pharmaceutical companies.

What does the future hold? With its R&D pipelines, the pharma industry has potential for improved treatments and increased revenues from blood-thinning agents. Many commercial opportunities remain.

Worldwide, numbers of heart attacks and strokes will rise this decade. Blood thinners will play important roles in medicine, helping to prevent and treat cardiovascular disorders.

Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You will find answers in our work.

-- Find revenue predictions to 2022 for the overall world market and submarkets

-- Discover revenue forecasts to 2022 for 14 drugs, assessing commercial potential

-- See revenue forecasts to 2022 for leading national markets - US, Japan, Germany, France, UK,Spain, Italy, China and India

-- Assess leading companies, discovering activities and outlooks

-- Review R&D, seeing pipeline trends

-- Investigate competition and opportunities influencing sales results

-- Find out what will stimulate and restrain the industry and market

-- View opinions from our survey of authorities on the sector.

There, you receive a distinctive mix of quantitative and qualitative work with independent predictions. We analyse developments and prospects, helping you to stay ahead.

Gain business research, data and analysis for treatment of blood clotting disorders

Our study is for everybody needing industry and market analyses for blood-thinning drugs. Find data, trends and answers. Avoid missing out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

1.1 Antithrombotic/Anticoagulant Drug: World Market Overview

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Blood Clotting: Mechanism, Disorders and Treatments 2.1 Thrombosis2.1.1 Venous Thrombosis2.1.2 Arterial Thrombosis2.2 Complications of Thrombosis2.2.1 Pulmonary Embolism2.2.2 Stroke2.2.3 Myocardial Infarction2.2.4 Acute Coronary Syndrome2.3 Antithrombotic Treatments2.3.1 Platelet Aggregation Inhibitors2.3.1.1 Glycoprotein Inhibitors2.3.1.2 Aspirin2.3.1.3 Thienopyridines2.3.2 Heparins2.3.3 Fibrinolytics2.3.3.1 Streptokinase and Urokinase2.3.3.2 Tissue Plasminogen Activator (tPA)2.3.3.3 Other Thrombolytic Agents2.3.4 Vitamin K Antagonists2.3.5 Direct Thrombin Inhibitors2.3.6 Direct Factor Xa Inhibitors

3. Antithrombotic Drugs: World Market 2012-2022

3.1 The Antithrombotic/Anticoagulant Drug Market in 2010

3.2 The Antithrombotic/Anticoagulant Drug Market Forecast 2012-2022

3.3 The Leading Antithrombotic/Anticoagulant Therapeutic Classes

3.3.1 The Leading Therapeutic Classes in 2010

3.3.2 Leading Therapeutic Class Forecast 2012-2022

3.4 Platelet Aggregation Inhibitors

3.4.1 Platelet Aggregation Inhibitors Dominated the Market in 2010

3.4.2 Platelet Aggregation Inhibitors: Market Forecast 2012-2022

3.5 Heparins

3.5.1 The Heparins Market in 2010

3.5.2 Heparins: Market Forecast 2012-2022

3.6 Fibrinolytics

3.6.1 The Fibrinolytics Market in 2010

3.6.2 Fibrinolytics: Market Forecast 2012-2022

3.7 Vitamin K Antagonists

3.7.1 Vitamin K Antagonists Market in 2010

3.7.2 Vitamin K Antagonists Market Forecast 2012-2022

3.8 Direct Thrombin Inhibitors

3.8.1 Direct Thrombin Inhibitors Market in 2010

3.8.2 Direct Thrombin Inhibitors: Market Forecast 2012-2022

3.9 Direct Factor Xa Inhibitors

3.9.1 Direct Factor Xa Inhibitors Market in 2010

3.9.2 Direct Factor Xa Inhibitors: Market Forecast 2012-2022

3.10 Chapter Summary

4. Leading National Markets for Antithrombotic/Anticoagulant Drugs, 2012-20224.1 Leading National Markets in 20104.2 Leading National Markets: Forecasts to 20224.3 The US Antithrombotic/Anticoagulant Drug Market, 2012-20224.4 The Japanese Antithrombotic/Anticoagulant Drug Market, 2012-20224.5 Leading European Antithrombotic/Anticoagulant Drug Markets, 2012-20224.6 The Chinese Antithrombotic/Anticoagulant Drug Market, 2012-20224.7 The Indian Antithrombotic/Anticoagulant Drug Market, 2012-2022

5. Leading Antithrombotic/Anticoagulant Drugs, 2012-2022

5.1 The Leading Drugs of 2010

5.2 Plavix - Commercial Prospects

5.2.1 Plavix: The Leading Anticoagulant of 2010

5.2.2 Plavix Sales Forecast, 2012-2022

5.2.3 Generic Competition

5.2.4 Branded Competition

5.3 Lovenox

5.3.1 Lovenox Sales Forecast, 2012-2022

5.3.2 Competition for Lovenox

5.4 Pletal

5.4.1 Pletal Sales, 2010

5.4.2 Pletal Sales Forecast, 2012-2022

5.5 Fragmin

5.5.1 Fragmin Sales, 2010

5.5.2 Fragmin Sales Forecast, 2012-2022

5.6 Asasantin

5.6.1 Asasantin Sales, 2010

5.6.2 Asasantin Sales Forecast, 2012-2022

5.7 Arixtra

5.7.1 Arixtra Sales, 2010

5.7.2 Arixtra Sales Forecast, 2012-2022

5.8 Aspirin Cardio

5.8.1 Aspirin Cardio Sales, 2010

5.8.2 Aspirin Cardio Sales Forecast, 2012-2022

5.9 Opalmon

5.9.1 Opalmon Sales, 2010

5.9.2 Opalmon Sales Forecast, 2012-2022

5.10 Angiomax

5.10.1 Angiomax Sales, 2010

5.10.2 Angiomax Sales Forecast, 2012-2022

5.11 Activase

5.11.1 Activase Sales, 2010

5.11.2 Activase Sales Forecast, 2012-2022

5.12 Newly Launched Drugs, 2009-2011

5.12.1 Eli Lilly's Effient

5.12.1.1 Effient Sales Forecast, 2012-2022

5.12.1.2 Competition for Effient

5.12.2 Boehringer Ingelheim's Pradaxa

5.12.2.1 Pradaxa Sales Forecast, 2012-2022

5.12.2.2 Competition for Pradaxa

5.12.3 AstraZeneca's Brilinta

5.12.3.1 Brilinta Sales Forecast, 2012-2022

5.12.3.2 Competition for Brilinta

5.12.4 Johnson & Johnson/Bayer's Xarelto

5.12.4.1 Xarelto Sales Forecast, 2012-2022

5.12.4.2 Competition for Xarelto

5.13 Chapter Summary

6. Antithrombotic/Anticoagulant Drug R&D Pipeline6.1 Platelet Aggregation Inhibitors R&D Pipeline, 2011 6.1.1 Portola/Novartis's Elinogrel6.2 Heparins R&D Pipeline, 20116.2.1 Sanofi's Semuloparin6.3 Fibrinolytics R&D Pipeline, 2011 6.3.1 Lundbeck/Berlex/Bayer's Desmoteplase6.4 Direct Thrombin Inhibitors R&D Pipeline, 2011 6.4.1 Merck's Vorapaxar6.4.2 Eisai's Atopaxar6.5 Direct Factor Xa Inhibitors R&D Pipeline, 2011 6.5.1 BMS/Pfizer's Apixaban6.5.2 Portola's Betrixaban6.5.3 Daiichi Sankyo's Edoxaban6.6 R&D Pipeline for Other Antithrombotic Drugs, 2011 6.6.1 Endotis/Merck's EP217609

7. SWOT and STEP Analyses

7.1 Principal Market Drivers

7.1.1 Rising Disease Prevalence

7.1.2 Risk Factors: Management Rather Than Cure

7.1.3 Opportunities for Continuous Growth

7.1.3.1 Standing Out from Competitors

7.1.3.2 Cost-Effective Replacement of Warfarin

7.1.3.3 Antidotes in Demand

7.1.3.4 Further Development of Existing Drugs

7.1.3.5 Exploring New Markets

7.1.4 Advances in Technology Will Bring Benefits to the Market

7.2 Principal Market Restraints

7.2.1 Highly Competitive Market

7.2.1.1 Generic Competition

7.2.1.2 Branded Competition

7.2.2 Cost-Reduction Pressure

7.2.3 Stringent Regulations

8. Research Interviews8.1 Interview with Dr Charles E. Mahan (Director of Outcomes Research, New Mexico Heart Institute,Albuquerque, New Mexico) 8.1.1 Unmet Needs8.1.2 Major Areas of Focus8.1.3 New Drug Potential8.1.4 Key Market Drivers8.1.5 Opportunities for Revenue Growth8.2 Interview with Dr Maurice Petitou (Head of Preclinical Research and Development, Endotis Pharma)8.2.1 EP217609: The First Neutralizable Anticoagulant8.2.2 Drug Targets Worth Exploring8.2.3 New Drug Potential8.2.4 Unmet Needs8.3 Interview with Dr Jonathan L. Halperin (Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York)8.3.1 Unmet Needs8.3.2 New Findings8.3.3 Warfarin Replacement8.3.4 Areas Demanding Attention8.3.5 Key Market Restraints8.4 Interview with Dr Jeffrey I. Weitz (Professor of Medicine & Biochemistry, McMaster University, and Executive Director, Thrombosis & Atherosclerosis Research Institute, Ontario)8.4.1 Unmet Needs8.4.2 New Oral Anticoagulants8.4.3 Future Areas of Focus8.4.4 New Drug Potential8.4.5 Market Drivers and Restraints

9. Conclusions

9.1 World Market Overview to 2022

9.2 Leading Drug Classes

9.3 Leading Products

9.4 Leading National Markets

9.5 The Future of the Antithrombotic/Anticoagulant Drug Market

9.5.1 Challenges

9.5.2 Opportunities

List of TablesTable 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2016Table 3.2 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2017-2022Table 3.3 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Sales ($bn) and Market Shares (%), 2010Table 3.4 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2010-2016Table 3.5 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2017-2022Table 3.6 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022Table 3.7 Heparins: Market Forecast ($bn), 2010-2022Table 3.8 Fibrinolytics: Market Forecast ($bn), 2010-2022Table 3.9 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022Table 3.10 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022Table 3.11 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022Table 4.1 Antithrombotic/Anticoagulant Drugs: Leading National Markets, 2010Table 4.2 Leading National Markets: Forecasts ($bn), 2010-2022Table 4.3 Antithrombotic/Anticoagulant Drug Market Shares (%) by Country, 2012 & 2022Table 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Table 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Table 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022Table 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Table 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Table 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010Table 5.2 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2010-2022Table 5.3 Plavix Sales Forecast ($m), 2010-2022Table 5.4 Lovenox Sales Forecast ($m), 2010-2022Table 5.5 Pletal Sales Forecast ($m), 2010-2022Table 5.6 Fragmin Sales Forecast ($m), 2010-2022Table 5.7 Asasantin Sales Forecast ($m), 2010-2022Table 5.8 Arixtra Sales Forecast ($m), 2010-2022Table 5.9 Aspirin Cardio Sales Forecast ($m), 2010-2022Table 5.10 Opalmon Sales Forecast ($m), 2010-2022Table 5.11 Angiomax Sales Forecast ($m), 2010-2022Table 5.12 Activase Sales Forecast ($m), 2010-2022Table 5.13 Newly Launched Drugs, 2009-2011Table 5.14 Effient Sales Forecast ($m), 2010-2022Table 5.15 Pradaxa Sales Forecast ($m), 2011-2022Table 5.16 Brilinta Sales Forecast ($m), 2011-2022Table 5.17 Xarelto Sales Forecast ($m), 2011-2022Table 6.1 Platelet Aggregation Inhibitors: R&D Pipeline, 2011Table 6.2 Heparin Drugs: R&D Pipeline, 2011Table 6.3 Fibrinolytics: R&D Pipeline, 2011Table 6.4 Direct Thrombin Inhibitors: R&D Pipeline, 2011Table 6.5 Direct Factor Xa Inhibitors: R&D Pipeline, 2011Table 6.6 R&D Pipeline for Other Antithrombotic Agents, 2011Table 7.1 SWOT Analysis, 2012-2022Table 7.2 STEP Analysis, 2012-2022Table 9.1 World Market Forecast ($bn), 2010-2022

List of Figures

Figure 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Figure 3.2 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Market Shares (%), 2010Figure 3.3 Leading Therapeutic Class Forecast: Market Shares (%), 2012Figure 3.4 Leading Therapeutic Class Forecast: Market Shares (%), 2022Figure 3.5 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022Figure 3.6 Heparins: Market Forecast ($bn), 2010-2022Figure 3.7 Fibrinolytics: Market Forecast ($bn), 2010-2022Figure 3.8 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022Figure 3.9 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022Figure 3.10 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022Figure 3.11 Antithrombotic/Anticoagulant Drugs: Therapeutic Class Market Shares (%), 2010, 2012 & 2022Figure 4.1 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2010Figure 4.2 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2012Figure 4.3 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2022Figure 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Figure 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Figure 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022Figure 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Figure 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022Figure 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010Figure 5.2 Plavix Sales Forecast ($m), 2010-2022Figure 5.3 Lovenox Sales Forecast ($m), 2010-2022Figure 5.4 Pletal Sales Forecast ($m), 2010-2022Figure 5.5 Fragmin Sales Forecast ($m), 2010-2022Figure 5.6 Asasantin Sales Forecast ($m), 2010-2022Figure 5.7 Arixtra Sales Forecast ($m), 2010-2022Figure 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2022Figure 5.9 Opalmon Sales Forecast ($m), 2010-2022Figure 5.10 Angiomax Sales Forecast ($m), 2010-2022Figure 5.11 Activase Sales Forecast ($m), 2010-2022Figure 5.12 Effient Sales Forecast ($m), 2010-2022Figure 5.13 Pradaxa Sales Forecast ($m), 2011-2022Figure 5.14 Brilinta Sales Forecast ($m), 2011-2022Figure 5.15 Xarelto Sales Forecast ($m), 2011-2022Figure 6.1 New Antithrombotic AgentsFigure 9.1 Leading Drug Classes: Sales Forecasts ($bn), 2010-2022Figure 9.2 Leading Drugs: Sales Projections ($m), 2010, 2012 & 2022Figure 9.3 Leading National Markets: Sales Projections ($bn), 2010, 2012 & 2022

Ablynx

Acino Pharma

ARCA Discovery

Archemix

Arena Pharmaceuticals

Artisan Pharma

Asahi Kasei Pharma

AstraZeneca

ARYx Therapeutics

Barr Pharmaceuticals

Bayer Healthcare

Berlex

Bharat Biotech

BioInvent

BioVascular

Boehringer Ingelheim

Bristol-Myers Squibb (BMS)

Canyon Pharmaceuticals

Cardiome Pharma

Center for Medicaid and Medicare Services

Daiichi Sankyo

Dainippon Sumitomo

Dr. Reddy's Laboratories

Eisai Pharmaceuticals

Eli Lilly

Endotis Pharma

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)

Genentech

GlaxoSmithKline (GSK)

Janssen

Johnson & Johnson (J&J)

Kowa

Kyowa Hakko

LIMES Institute

Lundbeck

McMaster University

Merck & Co.

Mitsubishi Kasei

Momenta

Myriad Genetics

New Mexico Heart Institute

Novartis

Ono Pharmaceutical

Organon

Otsuka Pharmaceuticals

PAION

Pfizer

Pharmacia

Pharmacyclics

Polymedix

Portola Pharmaceuticals

POZEN

Ranbaxy

Regado Biosciences

Roche

Rovi Pharmaceuticals

Sandoz (part of Novartis)

Sanofi

Speedel

Takeda Pharmaceutical

Talecris Biotherapeutics

Teva Pharmaceuticals

The Medicines Company

The Mount Sinai Medical Center

Trigen Pharma

ThromboGenics

Thrombosis & Atherosclerosis Research Institute, Ontario

Virginia Commonwealth University

Watson Pharmaceuticals

Western Therapeutics Institute

World Health Organization (WHO)

Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center

More

Check our

Nicolas Bombourg Reportlinker Email: nicolasbombourg@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
COPYRIGHT 2012 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 9, 2012
Words:2917
Previous Article:Global Smart Cards Industry.
Next Article:China Power Equipment to Host First Quarter 2012 Earnings Conference Call on Tuesday, May 15, 2012 at 8:00 am ET.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters